Inhibitors of COX activity preserve muscle mass in mice bearing the Lewis lung carcinoma, but not the B16 melanoma

Research in Nursing & Health
Erin GravesDonna O McCarthy

Abstract

Tumor-induced skeletal muscle wasting (SMW) contributes to the fatigue and weakness experienced by persons with cancer cachexia. Tumor necrosis factor-alpha (TNFa) and cyclooxygenase (COX) activity have been implicated in SMW in some animal models of cancer cachexia. We report that indomethacin, a nonspecific inhibitor of COX, and NS398, a specific inhibitor of COX2, preserved muscle mass and reduced type 1 TNF receptors in muscles of mice bearing the Lewis lung carcinoma, but not in mice bearing the B16 melanoma. These data suggest that tumor-induced SMW can occur via a COX2-independent pathway. The COX2-dependent pathway may involve reducing the catabolic effects of TNFa in muscle. Further study is needed to understand the relationship between COX and SMW, and whether patients with cancer cachexia might benefit from COX inhibitors.

References

Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·J L MasferrerK Seibert
Sep 26, 2000·American Journal of Physiology. Cell Physiology·B X ZhangM S Katz
Apr 16, 2002·British Journal of Cancer·N CarbóJ M Argilés
Jul 11, 2003·World Journal of Gastroenterology : WJG·Wei ZhouJie-Shou Li
Jan 9, 2004·The Journal of Pharmacology and Experimental Therapeutics·Thomas W DavisJaime L Masferrer
May 7, 2004·Journal of Perinatology : Official Journal of the California Perinatal Association·Laura L Jelliffe-Pawlowski, Robin L Hansen
May 14, 2004·Research in Nursing & Health·Donna O McCarthySadeeka Al-Majid
Oct 14, 2004·Cell·Dongsheng CaiSteven E Shoelson
Mar 4, 2005·Archives of Pharmacal Research·Young-Joon Surh, Joydeb Kumar Kundu
Mar 5, 2005·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Yi-Ping LiMichael B Reid
Apr 6, 2005·Current Opinion in Clinical Nutrition and Metabolic Care·Christopher Deans, Stephen J Wigmore
May 10, 2005·The International Journal of Biochemistry & Cell Biology·Josep M ArgilésFrancisco J López-Soriano

❮ Previous
Next ❯

Citations

Dec 21, 2010·Life Sciences·Hui XuLoren E Wold
Oct 27, 2015·Life Sciences·Diana M NordenLoren E Wold
Apr 5, 2014·Autonomic Neuroscience : Basic & Clinical·Tilman GraulichChristian Mühlfeld
Sep 20, 2016·Oxidative Medicine and Cellular Longevity·Mohamad Assi, Amélie Rébillard
Oct 21, 2006·Current Opinion in Rheumatology·Stephen M RothLuigi Ferrucci
Feb 8, 2007·American Journal of Physiology. Endocrinology and Metabolism·Miriam GranadoAsunción López-Calderón
May 7, 2016·Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·Masahiro OhsawaKazuhiko Kume
Sep 19, 2014·Biological Research for Nursing·Yvonne Y ClarkDonna O McCarthy
Feb 18, 2015·Cancer Nursing·Ann O'Mara

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cachexia & Brown Fat

Cachexia is a condition associated with progressive weight loss due to severe illness. In cancer patients, it is proposed to occur as a result of tumor-induced energy wasting. Several proteins have been implicated in browning and depletion of white adipose tissue. Here is the latest research on cachexia and brown fat.

Cardiac Cachexia

Cardiac cachexia is a syndrome associated with the progressive loss of muscle and fat mass. It most commonly affects patients with heart failure and can significantly decrease the quality of life and survival in these patients. Here is the latest research on cardiac cachexia.

Related Papers

The Journal of Pharmacology and Experimental Therapeutics
Thomas W DavisJaime L Masferrer
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
R SandströmK Lundholm
International Journal of Oncology
Min TianMartha A Belury
© 2021 Meta ULC. All rights reserved